Australia's most trusted
source of pharma news
Sunday, 22 December 2024
Posted 26 July 2024 AM
It took longer than expected, but MSD's monoclonal antibody Keytruda has finally made it to the top of the quarterly PBS reimbursements table.
Keytruda was the top-selling drug globally in 2023, but was held out of first place in Australia by Vertex's cystic fibrosis treatment Trikafta. Despite huge sales in 2023, Trikafta reached an even greater peak in reimbursements in January this year, which saw it cling to the top spot in the first quarter.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.